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Abstract: Staphylococcal enterotoxin B (SEB) and related superantigenic toxins are potent 
stimulators of the immune system and cause a variety of diseases in humans, ranging from 
food poisoning to toxic shock. These toxins bind directly to major histocompatibility complex 
(MHC) class II molecules on antigen-presenting cells and specific V regions of T-cell 
receptors  (TCR),  resulting  in  hyperactivation  of  both  monocytes/macrophages  and 
T lymphocytes. Activated host cells produce massive amounts of proinflammatory cytokines 
and chemokines, activating inflammation and coagulation, causing clinical symptoms that 
include fever, hypotension, and shock. This review summarizes the in vitro and in vivo effects 
of staphylococcal superantigens, the role of pivotal mediators induced by these toxins in the 
pathogenic mechanisms of tissue injury, and the therapeutic agents to mitigate the toxic effects 
of superantigens. 
Keywords: staphylococcal superantigens; therapeutics; inflammatory mediators; toxic shock; 
murine models  
 
1. Staphylococcal Exotoxins as Superantigens 
1.1. Overview 
Staphylococcus aureus, a ubiquitous gram-positive coccus, produces several exotoxins: staphylococcal 
enterotoxins A through R (SEA-SER), and toxic shock syndrome toxin 1 (TSST-1), which contribute to its 
ability to cause disease in humans and laboratory animals [1–8]. These exotoxins bypass the normal 
mechanism  of  conventional  antigen  processing,  bind  outside  the  peptide-binding  groove  of  major 
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histocompatibility complex (MHC) class II molecules on antigen-presenting cells (APC) and specific V 
regions of T-cell receptors (TCR), to polyclonally activate T cells [2,9]. Originally known for their 
pyrogenicity, these bacterial toxins are called ―superantigens‖ because of their potency in stimulating 
T cells at picomolar concentrations [2,9]. The dual affinity of staphylococcal superantigens for MHC class 
II molecules and specific TCR V chains enables these microbial toxins to perturb the immune system and 
induce high levels of proinflammatory cytokines, chemokines, tissue factor, lytic enzymes, and reactive 
oxygen species, activating both inflammatory and coagulation pathways [10–19]. Important inflammatory 
cytokines, tumor necrosis factor  (TNF) and interleukin 1 (IL-1) appear early, and in conjunction with 
other cytokines and chemokines they elicit fever, hypotension, and shock [20]. Interferon (IFN), a 
prominant T-helper type 1 (Th1) cytokine, acts synergistically with TNF and IL-1 to promote immune 
reaction and tissue injury. IL-2, from superantigen-activated T cells, causes vasodilation and contributes to 
vascular leak and edema [21]. The chemokines, IL-8, monocyte chemoattractant protein-1 (MCP-1), 
macrophage inflammatory protein 1α (MIP-1α), and MIP-1, are induced directly by SEB or TSST-1 and 
selectively activate and direct migration of leukocytes, neutrophils and dendritic cells to sites of tissue 
injury [16,17]. These mediators are pathogenic at high concentrations in vivo and induce fever, organ 
dysfunction, and death. 
1.2. Physical properties of staphylococcal superantigens 
Staphylococcal enterotoxins (SEs) and TSST-1 are 22 to 30 kD single-chain globular proteins with 
well-conserved  tertiary  structures  [22].  Based  on  amino  acid  sequence  alignment,  staphylococcal 
superantigens can be grouped into three subfamilies [6–8,23]. SEA, SED, SEE, SHE, and SEI share the 
highest sequence homology, between 53% and 81%. The second group is comprised of SEB, the SECs, 
and SEG, which are 50% to 66% homologous. Finally, TSST-1 has only 28% identity with the rest of the 
SEs as it has a distinct, shorter primary sequence of 194 amino acids with no cysteines and a missing 
"disulfide loop" commonly found in SEs. This disulfide loop has been proposed to be associated with the 
emetic properties of SEs, as mutation of residues in this loop eliminated the emetic effects of SEC1. 
Crystallographic studies of staphylococcal superantigens reveal similarities in the secondary-tertiary 
structure with two conserved, tightly packed domains. The N-terminal β-barrel domain resembles the 
oligosaccharide/oligonucleotide-binding (OB) fold found in other unrelated proteins, while the C-terminal 
domain has a β-grasp motif [22]. The relatively conserved TCR-binding site is located in the shallow 
groove between these two domains [22,24]. 
1.3. Human diseases caused by staphylococcal superantigens 
SEB is the prototypic and most widely studied superantigen and is listed by the Centers for Disease 
Control and Prevention (CDC) as a category B priority agent because it can be used as an air-borne,  
food-borne, and water-borne toxic agent. These bacterial toxins have profound effects on the immune 
system through the action of proinflammatory cytokines which affect local and distant sites of infection. 
Depending on the dose and route of exposure, SEB and other SEs cause food poisoning, acute and fatal 
respiratory distress, autoimmune diseases, and toxic shock [3,7,11,25]. 
Staphylococcal toxic shock syndrome is characterized by fever, hypotension, desquamation of skin, 
fever, and dysfunction of three or more organ systems [1]. Microbial superantigens are also causative Toxins 2010, 2  
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agents of autoimmune diseases, as shown in several animal models by their ability to activate APC and 
normally quiescent, autoreactive T- and B- cells [26–29]. In humans, there is a good correlation between 
the presence of SEB-specific IgM and arthritis, suggesting a role for this toxin in disease [30]. TSST-1 
may also be associated with Kawasaki syndrome, a disease with immunoregulatory abnormalities [31,32]. 
Psoriasis and atopic dermatitis are autoimmune diseases also linked to staphylococcal and streptococcal 
colonization  of  skin  and  subsequent  production  of  exotoxins  like  SEA,  SEB,  SEC,  TSST-1,  and 
streptococcal pyrogenic exotoxins [3,29].  
2. Superantigen Binding to Host Cells 
2.1. Binding to MHC class II  
Superantigens bind to common, conserved elements of MHC class II molecules with relatively high 
affinity (Kd = 10
−8–10
−7 M) [33]. However, each individual toxin exhibits preferential binding to certain 
MHC isotypes, allowing for different modes of contact for superantigen with MHC class II [33–36].  
HLA-DR binds SE and TSST-1 better than HLA-DP or -DQ, and murine IE molecules bind better than IA 
[37,38]. Crystallographic analysis indicates two distinct sites on MHC class II molecules for superantigen 
binding. A common, low-affinity binding site is found on the invariant -chain of MHC class II and a 
high-affinity,  zinc-dependent  binding  site  is  located  on  the  polymorphic  -chain  [8,22,39–41]. 
Superantigens in the SEA subfamily can bind to both  and  chains of MHC class II, interacting with the 
OB fold and -grasp domain, respectively. This mode of superantigen and MHC class II interaction 
enables the toxin to bind to both sides of the molecule and cross-link MHC class II on antigen-presenting 
cells (APC) [40]. Cross-linking allowed SEA to persist on the surface of APC and prolonged their 
exposure and effects on T cells [42]. SEB and TSST-1 bind only to the generic low-affinity site using the 
solvent-exposed, hydrophobic core at the N-terminal of the superantigen [38,39]. 
2.2. Binding to TCR  
The interaction of each toxin with the TCR V chain is unique, as shown by the different V 
specificities of each superantigen [2,3,9]. Members of the same subgroup interact and stimulate a different 
but overlapping TCR V. For example, SEB stimulates human T cells bearing V 1.1, 3.2, 6.4, 15.1, while 
another member of this group, SEC1, binds T cells with V 3.2, 6.4, 6.9, 12, 15.1 [8]. The binding contacts 
are mostly between the side-chain atoms of the superantigen and the complementarity-determining 
regions 1 and 2 and the hypervariable region 4 within the V chain. Superantigens bind TCR V with low 
affinity (Kd = 10
−4–10
−6 M), similar to those of conventional MHC/peptide/TCR V interactions. The 
mitogenic potency of these toxins results from a cooperative interaction such that the superantigen/MHC 
complex binds the TCR with a higher affinity than toxin alone. 
2.3. Co-stimulatory molecules on host cells 
As with conventional antigens, optimal cell activation requires the expression of co-stimulatory 
molecules on APC and T cells. These co-stimulatory molecules provide potent signals in addition to TCR 
engagement and influence T cell differentiation into major subsets of T cells, Th1, Th2, and Th17 cells. 
Intercellular adhesion molecule (ICAM) on an APC promotes stable cell conjugate formation and is a key Toxins 2010, 2  
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co-stimulatory signal and adhesion molecule for many cell types [43]. A requirement for IL-2 induction 
from superantigen-stimulated T cells is the activation of the CD28-regulated signal transduction pathway 
[44]. Co-stimulatory pairs of LFA-1/ICAM-1, CD80/CD28 and CD40/CD154 on APC and T cells 
contribute to modulating immune responses to both conventional antigens and superantigens [43–47]. 
Other cell surface molecules besides CD11a/ICAM-1, such as CD2 and ELAM, are also required for 
optimal activation of endothelial cells and T cells by SEB [45]. 
3. Immune Activation  
3.1. Signal transduction  
The main target cells of superantigens are the CD4
+ T cells and mononuclear phagocytes bearing MHC 
class II molecules [2,48–51]. Engagement of superantigen with MHC class II and TCR on APC and 
T cells,  respectively,  activates  intracellular  signaling  through  receptor  clustering.  In  T-cell  clones, 
phosphatidyl  inositol  production  and  intracellular  Ca
2+  flux  were  early  responses  elicited  by  high 
concentrations of SEB [51]. Similar to mitogens and other cross-linking ligands of MHC class II, 
superantigens also activate protein kinase C (PKC) and protein tyrosine kinase (PTK) pathways [52,53]. 
Ultimately, activation of transcriptional factors NF-B and AP-1 by superantigens results in the expression 
of proinflammatory cytokines, chemokines, and adhesion molecules on macrophages and T cells [51,53]. 
Additionally, the mediators produced by these superantigen-activated cells exert potent effects on the 
immune and cardiovascular system, resulting in multi-organ dysfunction and lethal shock (Figure 1) [54].  
Figure 1. Cells and mediators participating in superantigen-induced toxic shock. Reproduced 
with permission from [54]. 
 
3.2. In vitro cellular response  
Human peripheral blood mononuclear cells (PBMC) have been used extensively to study the cellular 
requirements for activation by staphylococcal superantigens, as these cells are sensitive to nanomolar 
concentrations of toxins. Superantigen-activated PBMC secrete the cytokines IL-1, IL-2, IL-6, IL-12, 
TNF, TNF, IFN; the chemokines, IL-8, MCP-1, MIP-1, MIP-1 [10–18]. Both monocytes and Toxins 2010, 2  
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T cells are required for optimal induction of mediators as cognate interaction of superantigen bound on 
APC with T cells contributes to the production of these cytokines and chemokines [14,17,48,49]. Most of 
the mediators are induced as early as 5 h and are present as late as 72 h, whereas superantigen-induced 
T cell proliferation appears later, reaching maximum levels at 48 to 72 h. Direct superantigen presentation 
to T cells in the absence of MHC class II molecules can induce an anergic response [55].  
Other cell types responding directly to staphylococcal superantigen include synovial fibroblasts, 
B cells,  mast  cells,  intestinal  myofibroblasts,  intestinal  and  vaginal  epithelial  cells  [56–59].  
Superantigen-activated synovial fibroblasts triggered chemokine gene expression, raising the possibility 
that superantigens can be a causative agent for inflammatory arthritis [57]. Internalized SEB was found in 
lysosomal compartments of human B cells [42] whereas in an intestinal epithelial cell line, transcytosis of 
SEB across the cell was observed [58]. The interactions of most superantigens with epithelial and 
endothelial  cells/cell  lines  are  mostly  indirect,  via  the  release  of  IL-1,  TNF,  and  IFN  from  
superantigen-activated APC and T cells [60,61]. In vivo, SEB was shown to penetrate the gut lining, 
evoking local and systemic immune response [62]. Vaginal epithelial cells were shown to bind a 
dodecapeptide of amino acids conserved in all superantigens [59]. In response to SEA but not SEB, human 
intestinal myofibroblasts elicited IL-6, IL-8, and MCP-1 [63].  
3.3. Signaling and biological effects of proinflammatory mediators  
TNF and IL-1 have overlapping and similar biological effects. Each can induce the production of 
other cytokines, chemokines, and cell adhesion molecules with potent immunological and vascular effects 
[20]. These two proinflammatory cytokines each activate the transcription factor NF-B independently in 
many cell types that include epithelial and endothelial  cells and synergizes with IFN to enhance 
immunological reactions. The individual and synergistic action of these three cytokines increases the 
expression of MHC class II, adhesion molecules, and tissue factor on endothelial cells, resulting in 
disseminated intravascular coagulation. On epithelial cells, these cytokines decrease trans-epithelial 
resistance and increase ion fluxes and protein transport. The receptors, adaptors, and the signaling 
molecules  used  by  these  three  cytokines  are  vastly  different  and  represent  three  families  of 
cytokine receptors.  
IL-1,  an  endogenous  pyrogen,  interacts  with  IL-1  receptor  1  (IL-1R1)  subsequently  activating 
downstream signaling molecules: the adaptor myeloid differentiation factor (MyD88), IL-1R-associated 
protein kinase (IRAK), and TNF receptor-associated factor 6 (TRAF-6) (Figure 2) [20]. Although toll-like 
receptors (TLRs) are not used for superantigen signaling, there are many similarities between the 
intracellular adaptors and signaling molecules used by the IL-1R and TLRs. The TLRs are conserved 
type 1 transmembrane receptors used by pathogen associated or released molecules to stimulate host innate 
immune responses [64]. Lipoproteins from gram-negative bacteria and lipopolysaccharide (LPS) from 
gram positive bacteria use TLR2 and TLR4, respectively, to activate NF-B through the MyD88-dependent 
pathway, activating downstream IB kinases (IKK). The phosphorylation of IB by IKK releases it from 
p50 and p65 of NF-B, allowing for the translocation of NF-B to the nucleus where it binds to promoter 
regions of many inflammatory genes [65,66]. Activation of NF-B leads to induction of proinflammatory 
genes as well as antiapoptotic genes.  Toxins 2010, 2  
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Figure 2. Cell receptors, intracellular pathways and signaling molecules used by superantigens 
and mediators induced by superantigens. 
 
TNF and TNF, bind to TNF receptors (TNFR) and use intracellular TRAFs different from those used 
by IL-1R or TLR, but ultimately activating NF-B, resulting in expression of cytokines and co-stimulatory 
molecules [20,67]. However, the TNFR possesses death domains, commonly present in receptors of the 
TNFR family, and binding of TNF to TNFR also triggers cell death through caspase activation. IFN binds 
to IFNR, has many immunomodulatory properties different from IL-1 and TNF, but synergizes with these 
two cytokines in enhancing immune reactions [68]. IL-6 has some overlapping activities with IL-1 and 
TNF [69]. Together and individually, these three cytokines act on the liver to release acute phase 
proteins, activate apoptopic pathways and decrease liver clearance function.  
Various chemokines from superantigen-activated cells attract neutrophils, T cells, dendritic cells, 
monocytes, and other cell types through seven-transmembrane G-protein-coupled receptors, induce early 
Ca
++ flux, and activating phospholipase Cβ [20,70]. Cytokine- and chemokine-activated neutrophils, Toxins 2010, 2  
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sequestered to sites of tissue injury and inflammation, produce reactive oxygen species (ROS) and 
proteases contributing to organ dysfunction. This is particularly important in the lung where systemic 
administration of SEB caused acute lung injury characterized by increased expression of adhesion 
molecules ICAM-1 and VCAM, increased neutrophils and mononuclear cells infiltrate, endothelial cell 
injury, and increased vascular permeability [71]. Intranasal delivery of SEB induced a prolong lung injury 
which was evident even after four days of steroid treatment [72]. Exudates from superantigen-injected air 
pouches were predominantly neutophils with some macrophages [16]. Endothelial cells surrounding air 
pouches expressed ICAM-1, TNF, MIP-2 (an IL-8 related protein in mice), MIP-1, and JE. Thus, 
systemic release of inflammatory mediators affects multiple organs and cell types resulting in decreased 
peripheral  vascular  resistance,  multi-organ  failure,  hypotension,  and  shock.  In  vivo,  SEB  induced  
V8-specific  T  cell  proliferation  but  these  cells  were  rapidly  deleted  in  the  periphery  by  
Fas-FasL-dependent apoptosis [73].  
4. Animal Models  
4.1. Host response, administration route and dose effects 
Microbial infections are complex diseases where invading pathogens must establish mechanisms to 
evade host detection and innate inflammatory responses for survival. Bacterial superantigens are among 
one group of virulence factors released by microbes and contribute to septic complications during infection 
[74,75]. Toxic shock syndrome represents a spectrum and progression of clinical features including  
multi-organ failure in humans exposed to bacterial toxins and/or concurrent bacterial infection, pathogenic 
features seemingly absent in most mouse models. In addition, humans are more sensitive to SEB 
intoxication and low doses are enough to cause lethal shock without the use of synergistic agents. In  
non-human primates, inhalation of lower, sublethal nanogram doses of aerosolized SEB caused severe 
incapacitation.  TNF  was  completely  absent,  although  IL-2  and  IL-6  were  found  in  sera  of  this 
incapcatitation nonhuman primate model [76]. Microgram levels of aerosolized SEB in monkeys resulted 
in emesis and diarrhea that developed within 24 h of exposure, followed by the abrupt onset of lethargy, 
difficult breathing, hypotension, fever, and finally death from toxic shock [77]. Edema, leukocytic 
infiltration, and lesions were apparent in lung tissues in this model. The route of SE administration also 
influenced the pattern of cytokine expression. Intrathymic SEB administration induced a switch from Th1 
to Th2 cytokine expression in the spleen [78]. Our own studies indicate that airway exposure was more 
potent in inducing lethality as lower intranasal (IN) doses can be used compared with just intraperiteonel 
(ip) injections [79].  
4.2. Emetic response models  
In  humans  and  monkeys,  SEs  induced  an  emetic  response  and  toxic  shock  at  submicrogram 
concentrations [80]. Oral administration of SEB induces activation and expansion of murine V8
+ T-cells 
in Peyer’s patches, accompanied by increased IFN and IL-2 mRNA expression [81]. The enteric effects of 
SEs likely resulted from IL-2 release from activated T cells as IL-2 given to cancer patients produces side 
effects similar to staphylococcal food poisoning. The release of cysteinyl leukotrienes by mast cells and 
substance P from sensory neurons was responsible for emesis [56,82]. Recently, rapid release of serotonin Toxins 2010, 2  
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and intestinal production of 5-hydroxytryptamine was seen in an emetic model using SEA [83]. Mice have 
no emetic response upon ingestion of high doses of SEs and are not suitable as emetic models. 
4.3. Murine models of toxic shock using potentiating agents 
Investigations of SEs in murine models of toxic shock have relied on potentiation agents to amplify the 
toxic effects of SEs as mice are poor responders to SEs due to lower affinity of these toxins to mouse 
MHC class II [84,85]. Sensitizing agents such as D-galactosamine (D-gal), actinomycin D, LPS, or viruses 
are used together with superantigens to induce toxic shock [84–91]. Depending on the injury model and 
adjunctive agents used, severity of disease may involve different organs and different pattern of mediators. 
Both D-gal and actinomycin D induced TNF-dependent hepatotoxicity and SEB-induced shock models 
using these agents encountered much higher levels of TNF not present when SEB was used alone and 
liver dysfunction was a prominent feature in these models. IL-2 deficient mice were resistant to SEB-induced 
shock in D-gal sensitized mice demonstrating the importance of IL-2 besides TNF [92]. Antibodies to 
IFN inhibited SEB-induced weight loss and hypoglycemia but had no effect on mortality [93].  
LPS, a cell wall component of gram negative bacteria, is the most frequently used potentiating agent in 
mouse models of SEB-induced shock. In these models, relatively high doses of SEB were administered via 
the aerosol, IN or i.p. route, followed by i.p. injections of LPS to induce shock [84,94–97]. LPS naturally 
synergizes with superantigens to induce the proinflammatory cytokine cascade and a correlation was found 
between increased serum levels of IL-1, IL-2, TNF, and IFN with SEB-induced shock [84,94–97]. The 
shock syndrome induced by superantigens in these models results from the culmination of biological 
effects of much higher levels of IL-1, TNF, and IFN, not seen when LPS was absent. It is difficult to 
determine  if  any  one  particular  cytokine,  and  at  what  serum  concentration,  is  required  to  cause  
SEB-induced toxic shock, as LPS induces the same proinflammatory cytokines and chemokines (TNF, 
IL-1, IFN, IL-6, IL-8 and MCP-1) as superantigens. A recent study analyzed the interdependent effects of 
doses of SEB used alone and together with LPS in different combination of doses on serum levels of 
cytokine/chemokine in Balb/c mice, the most common mouse strain used in LPS potentiated SEB shock 
model [98]. In vivo, SEB alone induced only moderate levels of IL-2 and MCP-1 and all mice survived 
even with a high dose of SEB (100 µ g/mouse). LPS (80 µ g/mouse) alone caused 48% lethality and 
induced high levels of IL-6 and MCP-1. SEB induced low levels of TNFα, IL-1, IFN, MIP-2 and LPS 
synergized with SEB in the expression of these cytokines as well as those of IL-6 and MCP-1. Importantly, 
the synergistic action of SEB and LPS resulted in lethal shock and hypothermia not seen in SEB only or 
low doses of LPS. Cytokine levels by survival status in SEB plus LPS groups revealed significantly higher 
levels of TNFα, IL-6, MIP-2, and MCP-1 in non-survivors early after SEB administration. In addition to 
these cytokines and chemokines, significantly higher levels of IFN and IL-2 were observed at later times 
in non-survivors of toxic shock compared to those in survivors. In this LPS-potentiated SEB-induced 
shock model, the higher cytokine response, especially at the later time point, was influenced mostly by the 
LPS dose. Thus, the synergistic action of SEB and LPS promoted early TNFα release and prolonged the 
release of IL-6, IFN, IL-2, MIP-2, and MCP-1 in non-survivors. Overall, the higher as well as prolonged 
levels of these key cytokines led to acute mortality, with mice succumbing to toxic shock within 48 h when 
LPS was used together with SEB. Although there is a general agreement that Th1 cytokines, typified by 
IFN, are important in these potentiated models of SEB-induced shock, the role of Th2 cytokines cannot Toxins 2010, 2  
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be overlooked. IL-10, a prototypic Th2 cytokine, was detected in vivo after repeated superantigen 
stimulation [99–101]. IL-10-deficient mice showed increase levels of IL-2, IFN, TNF after SEB 
stimulation, and they were more susceptible to SEB-induced lethal shock [100]. Repeated superantigen 
exposure also generated immunosuppressive regulatory T cells with attendant IL-10 secretion and 
inhibited IL-2 production [102,103], accompanied by clonal deletion and apoptosis of some of these 
activated T cells [55,103].  
4.4. Transgenic mouse models  
The mechanism of SEB intoxication and therapeutic studies were also investigated using transgenic 
mice with human MHC class II [104–107]. Transgenics respond to much lower doses of toxins due to the 
higher affinity binding of SEs to human MHC class II molecules and high levels of serum IFN, IL-2, and 
IL-6 also correlated with mortality [106]. Although TNF was present in lungs of HLA-DQ8 transgenics 
exposed to aerosolized SEB, serum TNFα was absent in this study [106]. Pathological lesions in lungs of 
transgenics, temperature fluctuations, lethality starting later at 96 h, were similar to those in nonhuman 
primates exposed to lethal doses of SEB. Other investigations [105] suggested that two doses of relatively 
high amounts of SEB (30 to 100 g/mouse) were necessary to induce toxic shock in these transgenics, and 
the sensitizing agents D-gal was still required [107]. 
4.5. Murine models using only SEB  
A high IN dose of SEB was reported to be lethal in C3H/HeJ, a TLR4-defective mouse strain, but the 
mechanism of intoxication was unclear [108]. A recent study revealed that this dose of SEB was 
ineffective in mediating SEB-induced shock, although two low doses of SEB, at least one dose must be 
delivered by IN, were lethal [79]. This two-hit model required two doses of SEB strategically given 2 h 
apart with the first SEB dose delivered by IN and the subsequent dose of SEB administered either IN or by 
i.p. Increased serum levels of IL-2, IL-6, and MCP-1 accompanied by an early, high concentration of lung 
MCP-1 was seen in this dual-dosing model [79]. MCP-1, a potent activator and chemotactic factor for 
T cells as well as monocytes probably contribute to early leukocyte recruitment into the lung in this IN 
SEB-induced shock model. The proinflammatory cytokines, IL-1, TNFα, and IFN were found in lungs 
but not in serum of SEB-exposed C3H/HeJ mice. Pathological lesions, temperature fluctuations, and time 
course of lethality also resembled those seen in transgenics, nonhuman primates, and humans [77,106].  
5. Therapeutics for Superantigen-Induced Shock 
5.1. Influence of animal models on efficacy of therapeutics  
None of the existing mouse models completely reproduces all the complex events of human toxic shock 
syndrome as humans exposed to bacterial toxins often have concurrent bacterial infections. Each toxic 
shock model described in the previous section revealed the importance of different sets of cytokines and 
organ injury. In particular, the mouse models using potentiating agents such as actinomycin D, D-gal, or 
LPS created unrealistically higher levels of certain cytokines such as TNFα. As hepatic toxicity is  
TNFα-dependent, drugs designed to inhibit TNFα will have a higher therapeutic impact in models with 
TNFα-mediated toxicity. However, even nonhuman primate models for human disease in drug efficacy Toxins 2010, 2  
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testing is no guarantee of reproducibility of therapeutic effectiveness as demonstrated by the cytokine 
storm elicited in phase 1 trial of the monoclonal antibody to CD28 [109].  
Potential therapeutic targets to prevent the toxic effects of SEs include blocking the interaction of SEs 
with MHC or TCR, or other co-stimulatory molecules; inhibiting signal transduction pathways used by 
SEs; inhibiting cytokine and chemokine production; and blocking the downstream signaling pathways 
used by proinflammatory cytokines and chemokines. 
5.2. Antibodies against superantigens 
At  present,  intravenous  immunoglobulins  (IVIG)  is  the  only  therapeutic  available  for  treating 
staphylococcal exotoxin-induced shock [110]. Antibody-based therapy targeting direct neutralization of 
SEB or other superantigens is most suitable at the early stages of exposure before cell activation and 
release of proinflammatory cytokines. Some of the neutralizing antibodies against one superantigen can 
cross-react and prevent the biological effects of a diifferent superantigen [111]. Vaccinations with 
recombinant mutants of SEB, which lack superantigenicity and had attenuated binding to MHC class II, 
were able to protect mice and monkeys against SEB-induced disease [112].  
5.3. Inhibitors of cell receptor-toxin interaction 
Since the binding regions of SEB to MHC class II and TCR are well-characterized, small overlapping 
peptides of SEB were used as antagonists to block the initial step of receptor-toxin interactions [113,114]. 
Conserved peptides corresponding to residues 150–161 of SEB prevented SEA-, SEB-, or TSST-1-induced 
lethal shock in mice when given intravenously 30 min after an i.p. toxin dose [113]. This segment of SEB 
is not associated with the classically defined MHC class II or TCR binding domains, but it likely blocks 
co-stimulatory signals necessary for T-cell activation. However, a subsequent study indicated that these 
peptides were ineffective inhibitors of SEB-induced effects both in vitro and in vivo [114]. Another recent 
study with yet a different peptide, dodecapeptide P72, did not bind MHC class II, but inhibited SEA, SEB, 
and SEC-mediated responses [115].  
A different approach using a bi-specific chimeric inhibitor composed of the DR1 domain of MHC 
class II and V
 domain of the TCR specific for SEB connected by a flexible (GSTAPPA)2 linker bound 
SEB competitively and prevented its binding to MHC class II of APC and TCR on T cells [116]. These 
chimeric molecules blocked initial cellular activation and IL-2 release in SEB-stimulated PBMC. The 
drawback of this approach is that individual chimeras have to be constructed for each SE as TCR V
 
domains are different for each SE. Blockade of the CD28 co-stimulatory receptor by its synthetic ligand, 
CTLA4-Ig, prevented TSST-1-induced proliferation of T cells in vitro as well as lethal toxic shock in vivo 
[47]. Recently, polyphenols from apple juice were found to inhibit the biological activity of SEA in vitro 
and SEA was bound to constituents of apple juice [117]. 
5.4. Inhibitors of SEB signal transduction  
Blockade of SEB signal transduction pathways represents a more amenable mode of intervention as 
these events are postexposure and will likely work for other SEs. NF-B is an attractive therapeutic target 
as the activation of NF-B leads to the inducible expression of many of the mediators involved in 
inflammatory diseases. In vitro and in vivo studies have shown that many of the genes (i.e., cell adhesion Toxins 2010, 2  
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molecules, co-stimulatory molecules, cytokines, chemokines, acute phase proteins, and inducible nitric 
oxide synthase) that are implicated in superantigen-induced lethal shock contain NF-B binding sites in 
the promotor/enhancer region [65,66]. The nuclear import of NF-B from cytoplasm upon phosphorylation 
and removal of IBα allows transcriptional activation of over 100 genes that encode mediators of 
inflammatory responses and anti-apoptotic genes. Transient interruption of the NF-B pathway may 
therefore be beneficial for superantigen-induced shock. A cell-penetrating cyclic peptide (cSN50) targeting 
NF-B nuclear transport attenuated SEB-induced T cell responses and serum inflammatory cytokine [118]. 
Liver apoptosis
 and hemorrhagic necrosis and mortality were also reduced in mice given cSN50 before D-gal 
[119]. Administering cSN50 30 minutes prior to IN SEB in BALB/c mice reduced proinflammatory 
cytokines and chemokines in the bronchoalveolar space, attenuated neutrophil and monocytes infiltration 
to the lung and vascular injury [119]. Bortezomib, another NF-B inhibitor, decreased SEB- induced 
serum cytokines and chemokines levels but had no effect on mortality and liver necrosis in vivo [120]. 
Another potent NF-B inhibitor is dexamethasone, a well-known immunosuppressive drug used clinically 
to treat various inflammatory diseases. In vitro, dexamethasone potently inhibited staphylococcal exotoxin-
induced T-cell proliferation, cytokine release, and activation markers in human PBMC [15,72,97,121]. 
In vivo, dexamethasone also significantly reduced serum levels of cytokines and protected mice from  
SEB-induced shock in the two-hit SEB-only model and the SEB plus LPS model [72,97]. Furthermore, 
dexamethasone attenuated the hypothermic response to SEB in both models of toxic shock and improved 
survival of mice by 100% even when administered after SEB.  
Other signal transduction inhibitors include those directed against protein kinase C (PKC) and protein 
tyrosine kinase. H7, a PKC inhibitor and genistein, a tyrosine kinase inhibitor each blocked TNF but not 
IL-1 production from TSST-1-stimulated PBMC [122]. D609, an inhibitor of phospholipase C, which is an 
upstream activator of PKC, attenuated SE-induced effects both in vitro and in vivo [123,124]. Reduction in 
lethality was seen in mice treated with D609 and superantigen despite the unaltered high serum level of 
TNF [124].  
Recently,  another  FDA-approved  immunosuppressive  drug,  rapamycin  was  shown  to  protect  
SEB-induced shock even when administered 24 h after SEB [125]. Rapamycin is used clinically to prevent 
graft rejection in renal transplantation, as it shows less nephrotoxicity than calcineurin inhibitors [126]. 
Rapamycin inhibited T cell cytokines and likely interfered with other T cell signaling pathway induced 
by SEB. 
5.5. Inhibitors of cytokine induction 
Most therapeutic testing in animal models of SEB-induced shock have targeted proinflammatory 
cytokines,  as  there  is  a  strong  correlation  between  toxicity  and  increased  serum  levels  of  these 
inflammatory mediators, particularly when SEB is used with potentiating agents [93–97]. Neutralizing 
antibodies against TNF or soluble TNF receptor 1 prevented SEB-induced lethality, establishing the 
critical role of TNF in SEB-induced shock [86,87]. The anti-inflammatory cytokine IL-10 blocked the 
production of IL-1, TNF, and IFN, and reduced lethality to superantigen-induced toxic shock [101]. 
Another strategy is to attenuate IL-1 release from superantigen-activated cells is to target caspase 1, a 
proteolytic  enzyme  that  cleaves  pro-IL-1  into  active  IL-1  [20].  The  caspase  1  specific  inhibitor,  
Ac-YVAD-cmk, blocked IL-1 and MCP production in superantigen-stimulated PBMC cultures but had no Toxins 2010, 2  
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effect on other cytokines or T-cell proliferation [127]. A pan-caspase inhibitor, Z-D-CH2-DCB, attenuated 
the production of IL-1, TNF, IL-6, IFN, MCP, MIP-1, MIP-1, and inhibited T-cell proliferation in 
SEB- and TSST-1-stimulated PBMC [127]. In vivo, pan-caspase inhibitor delayed the time of death in the 
SEB plus LPS model but was ineffective in preventing mortality (unpublished observations). Because 
IFN acts in synergy with IL-1 and TNF, small amounts of IFN can profoundly affect the potentiation 
effects with IL-1 and TNF [20]. In vivo neutralization of IFN either protects or harms the host, 
depending on the mouse model and dose of sensitizing D-gal used [93].  
Other drugs tested to block cytokine release from superantigen-activated cells include doxycycline, an 
antibiotic, and pentoxyfylline, a methylxanthine derivative [95,128]. Doxycycline inhibited SEB-induced 
proinflammatory  cytokines  and  chemokines  and  T-cell  proliferation  in  human  PBMC  [128]. 
Pentoxyfylline, a phophodiesterase inhibitor, is used clinically to treat peripheral vascular disease. Its 
interference  with  intracellular  pathways  affects  leukocyte  adhesion  and  cytokine  production. 
Pentoxyfylline inhibited SEB- or TSST-1-induced toxic shock, as well as cytokine and chemokine release 
[15,95]. Dexamethasone, pentoxyfylline, doxycycline, and rapamycin are FDA-approved drugs used for 
other indications, and have been in clinical use for many years with a proven safety record. A list of small 
molecular weight inhibitors effective in blocking SEB-induced shock is shown in Table 1. 
Table 1. Small nonpeptide therapeutics for SEB-induced shock.  
Pharmacologic agent  Target  Biological effects against SEB 
Rapamycin 
FDA-approved for 
prevention of renal 
graft rejection 
Immunophilin 
FK506BP12  
Blocked SEB-induced MCP-1 and IL-6 in vitro 
and in vivo [125]. 
Protected mice from lethality even when 
administered 24 h after SEB. 
Dexamethasone 
FDA-approved for 
treating inflammatory 
diseases 
NF-B  Inhibited SEB-induced proinflammatory 
cytokines and chemokines in PBMC [72] and 
adhesion molecules (ICAM, ELAM, VCAM) 
on endothelial cells [121]. 
Reduced serum levels of cytokines, attenuated 
hypothermia due to SEB, improved survival of 
mice [72,97]. 
Pentoxifylline 
FDA-approved for 
treating peripheral 
arterial disease 
Phosphodiesterase   Attenuated SEB-induced proinflammatory 
cytokines and chemokines in PBMC [17,97]. 
Blocked cytokine release in vivo and prevented 
SEB-induced lethal shock in SEB + LPS murine 
models [97]. 
Pirfenidone  Inhibition of TGF 
(exact mechanism 
unknown) 
Inhibited SEB-stimulated cytokines in vitro and 
in vivo [96]. 
Improved survival of mice [96]. 
Niacinamide  Nitric oxide synthase  Inhibited serum IL-2 and IFN [94]. 
Prevented death of mice from SEB-mediated 
shock [94]. 
D609   Phospholipase C   Blocked SEB-stimulated cytokines, chemokines 
and proliferation in human PBMC [48]. 
Improved survival of mice [103]. Toxins 2010, 2  
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5.6. Inhibitors of cytokine signaling  
Blocking the signal transduction pathways used by inflammatory cytokines represents yet another 
means of inhibiting cellular responses to superantigens. One target is the suppressor of cytokine signal 3 
(SOCS3) which is an endogenous stop signal for IFNR-mediated responses and regulates the STAT family 
of proteins [68]. A cell-penetrating form of SOCS3 protected mice from the lethal effects of SEB and LPS 
by reducing production of inflammatory cytokines and attenuating liver apoptosis and hemorrhagic 
necrosis [129].  
6. Summary 
Proinflammatory cytokines act synergistically on multiple cells and organs resulting in cardiovascular 
derangement, multi-organ failure, and shock seen in SEB-induced diseases. The ability to stop the 
cytokine cascade and the inflammatory events initiated by cytokines early appears to be critical in 
preventing toxic shock. However, the tissue damage from cytokine storm lingers and resolution of 
inflammation, especially in the lungs, appears to be critical in preventing shock. 
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